Real-world analysis of outcomes and economic burden in patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a sample of the Italian population
This real-world analysis evaluated the clinical and economic burden of non-dialysis-dependent CKD patients with and without secondary hyperparathyroidism (sHPT) in Italy. An observational retrospective study was conducted using administrative databases containing a pool of healthcare entities covering 2.45 million health-assisted individuals. Adult patients with hospitalization discharge diagnoses for CKD stages 3, 4, and 5 were… Leggi tutto »Real-world analysis of outcomes and economic burden in patients with Chronic Kidney Disease with and without Secondary Hyperparathyroidism among a sample of the Italian population
La gestione terapeutica e il burden economico dei pazienti trattati con ESA affetti da insufficienza renale cronica non dipendente da dialisi con anemia: risultati da uno studio real-world in Italia
Background. L’obiettivo dell’analisi real-world è stato valutare le caratteristiche dei pazienti con insufficienza renale cronica non dipendente da dialisi (IRC-NDD) con anemia e trattati con agenti stimolanti l’eritropoiesi (ESA), analizzarne la farmaco-utilizzazione e il carico economico in pratica clinica italiana. Metodi. È stata eseguita un’analisi retrospettiva basata su database amministrativi e di laboratorio riguardanti circa… Leggi tutto »La gestione terapeutica e il burden economico dei pazienti trattati con ESA affetti da insufficienza renale cronica non dipendente da dialisi con anemia: risultati da uno studio real-world in Italia
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing… Leggi tutto »The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to… Leggi tutto »Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
Evaluation of the Impact of Catheter Ablation Procedure on Outcomes and Economic Burden in Patients with Atrial Fibrillation: Real-World Data from Italian Administrative Databases
Abstract: A real-world analysis among the Italian population has been carried out to estimate thenumber of atrial fibrillation (AF) patients undergoing catheter ablation and to evaluate their clinicaloutcome and economic burden. A retrospective analysis on administrative Italian databases hasbeen performed. Between January 2011 and December 2019, all patients diagnosed with AF wereconsidered and those undergoing… Leggi tutto »Evaluation of the Impact of Catheter Ablation Procedure on Outcomes and Economic Burden in Patients with Atrial Fibrillation: Real-World Data from Italian Administrative Databases
The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
Purpose: A retrospective analysis of real-world data was performed to assess the epidemiology and economic burden of multiple sclerosis (MS), relapsing-remitting MS (RRMS), and secondary-progressive MS (SPMS) in Italy.Patients and Methods: An observational study on administrative databases from a sample of Italian entities was carried-out.Between 01/2010–12/2017, patients with ≥1 MS diagnosis code (ICD-9-CM:340 and/or exemption… Leggi tutto »The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population
Anaemia is a uraemia-related complication frequently found in non-dialysis-dependent chronic kidney disease (ND-CKD) patients, with iron-deficiency anaemia (IDA) as the main underlying mechanism. Given the suboptimal anaemia management in ND-CKD patients with a co-diagnosis of IDA, this study evaluated the role of IDA therapy on clinical outcomes and healthcare resource consumptions in an Italian clinical… Leggi tutto »The Influence of Iron-Deficiency Anaemia (IDA) Therapy on Clinical Outcomes and Healthcare Resource Consumptions in Chronic Kidney Disease Patients Affected by IDA: A Real-Word Evidence Study among the Italian Population
Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources
Purpose: A retrospective analysis was conducted to estimate the number of patients with focal epilepsy and drug-resistant epilepsy (DRE) and their characteristics, the therapeutic patterns, the consumption of health resources in a real-world Italian setting.Patients and Methods: A retrospective study was carried out on the administrative databases of a sample of Italian Health Departments, covering… Leggi tutto »Analysis of Patients with Focal Epilepsy and Drug-Resistant Epilepsy in Italy: Evaluation of Their Characteristics, Therapeutic Pathway and the Consumption of Healthcare Resources
- « Precedente
- 1
- 2
- 3